Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Klein, C., Waldhauer, I., Nicolini, V.G., Freimoser-Grundschober, A., Nayak, T., Vugts, D.J., Dunn, C., Bolijn, M., Benz, J., Stihle, M., Lang, S., Roemmele, M., Hofer, T., van Puijenbroek, E., Wittig, D., Moser, S., Ast, O., Brunker, P., Gorr, I.H., Neumann, S., de Vera Mudry, M.C., Hinton, H., Crameri, F., Saro, J., Evers, S., Gerdes, C., Bacac, M., van Dongen, G., Moessner, E., Umana, P.
Oncoimmunology
